Atlas Trials

Shanghai Simnova Biotechnology Co.,Ltd.

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Shanghai Simnova Biotechnology Co.,Ltd.

RecordFirmDate
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus (NCT06468683)Shanghai Simnova Biotechnology Co.,Ltd.2024-06-15
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma (NCT06384482)Shanghai Simnova Biotechnology Co.,Ltd.2024-04-30
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (NCT06206902)Shanghai Simnova Biotechnology Co.,Ltd.2024-04-01
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM (NCT06616727)Shanghai Simnova Biotechnology Co.,Ltd.2023-12-26
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (NCT05563545)Shanghai Simnova Biotechnology Co.,Ltd.2022-07-21
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma (NCT05868083)Shanghai Simnova Biotechnology Co.,Ltd.2022-06-24
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT05346198)Shanghai Simnova Biotechnology Co.,Ltd.2021-03-12

Track Shanghai Simnova Biotechnology Co.,Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.